

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

**RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON AUGUST 5, 2022**

The Board is pleased to announce that all the Resolutions set out in the Notice were duly passed by way of poll by the Shareholders at the AGM held on August 5, 2022.

References are made to (i) the notice of the annual general meeting (the “**AGM**”) of Alibaba Health Information Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated July 6, 2022 (the “**Notice**”); and (ii) the circular of the Company dated July 6, 2022 (the “**Circular**”). Capitalized terms used herein shall have the same meanings as defined in the Circular unless the context requires otherwise.

RESULTS OF THE AGM

The board of directors (the “**Directors**”) of the Company (the “**Board**”) is pleased to announce that at the AGM held at Holiday Inn Express Hong Kong Causeway Bay, Meeting Room I & II, 7/F, 33 Sharp Street East, Causeway Bay, Hong Kong on Friday, August 5, 2022 at 10:30 a.m., all the resolutions set out in the Notice (the “**Resolutions**”) were duly passed by way of poll by the Shareholders. The poll results in respect of the Resolutions proposed at the AGM are as follows:

ORDINARY RESOLUTIONS		Number of Shares Voted (Approximate %)	
		For	Against
1.	To receive, consider and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor for the year ended March 31, 2022.	9,610,738,785 (99.99%)	1,367,161 (0.01%)
2.	(a) To re-elect the following retiring Directors:		
	(i) Mr. ZHU Shunyan as an executive Director;	9,136,842,624 (95.06%)	475,263,322 (4.94%)
	(ii) Mr. SHEN Difan as an executive Director;	9,579,983,865 (99.67%)	32,122,081 (0.33%)
	(iii) Mr. LI Faguang as a non-executive Director;	9,555,340,511 (99.41%)	56,765,435 (0.59%)
	(iv) Mr. LUO Tong as an independent non-executive Director; and	9,305,001,193 (96.81%)	307,104,753 (3.19%)
	(v) Mr. WONG King On, Samuel as an independent non-executive Director.	9,243,738,060 (96.17%)	368,367,886 (3.83%)
3.	To authorize the Board to fix the Directors’ remuneration.	9,611,423,529 (99.99%)	682,417 (0.01%)
4.	To re-appoint Ernst & Young as the auditor of the Company and to authorize the Board to fix its remuneration.	9,544,160,660 (99.29%)	67,945,286 (0.71%)
5.	To grant a general mandate to the Directors to issue and allot Shares.	8,522,727,996 (88.67%)	1,089,377,950 (11.33%)
6.	To grant a general mandate to the Directors to repurchase Shares.	9,609,605,946 (99.97%)	2,500,000 (0.03%)
7.	To approve the addition of the aggregate amount of Shares repurchased as mentioned in ordinary resolution no. 6 to the aggregate amount that may be issued and allotted pursuant to ordinary resolution no. 5.	8,558,177,153 (89.04%)	1,053,928,793 (10.96%)

ORDINARY RESOLUTIONS		Number of Shares Voted (Approximate %)	
		For	Against
8.	To approve the grant of a mandate authorizing the Directors to grant awards of options and/or RSUs pursuant to the Share Award Scheme in respect of a maximum number of the underlying new Shares that is equivalent to 3% of the Shares in issue as at the date of passing of this resolution during the period from the date of passing this resolution until the earlier of (a) the conclusion of the Company’s next annual general meeting, (b) the end of the period within which the Company is required by any applicable law or its bye-laws to hold its next annual general meeting, and (c) the date on which this resolution is varied or revoked by an ordinary resolution of the Shareholders in general meeting (the “ Applicable Period ”), and to allot, issue and deal with Shares underlying the options and/or RSUs granted pursuant to the Share Award Scheme during the Applicable Period as and when such options and/or RSUs vest.	8,840,444,289 (91.97%)	771,661,657 (8.03%)
SPECIAL RESOLUTION		For	Against
9.	(a) To approve the proposed amendments to the bye-laws of the Company (the “ Proposed Amendments ”), details of which are set out in the section headed “APPENDIX II — PROPOSED AMENDMENTS TO THE BYE-LAWS” in the circular of the Company dated July 6, 2022; and	9,611,643,946 (99.99%)	462,000 (0.01%)
	(b) To authorise any Director or company secretary of the Company to execute all such documents and do all such other acts and things as he or she may, in his or her absolute discretion, consider necessary, desirable or expedient to effect the Proposed Amendments and any of the foregoing.	9,611,643,946 (99.99%)	462,000 (0.01%)

Notes:

- (1) The full text of the Resolutions is set out in the Notice.
- (2) As at the date of the AGM:
 - (a) the total number of Shares in issue was 13,520,120,042.

- (b) each of the CP Trustee and the NCP Trustee held 1,019,517 and 4,938,397 Shares, respectively, representing approximately 0.01% and 0.04% of the issued share capital of the Company, respectively. Each of the CP Trustee and the NCP Trustee is not entitled to exercise any voting rights and is required to abstain from voting on Resolution no. 8 in relation to the 2022 Share Award Mandate. The CP Trustee and the NCP Trustee had abstained from voting on Resolution no. 8;
 - (c) the total number of Shares entitling the Shareholders to attend and vote for or against the Resolutions (other than Resolution no. 8) at the AGM was 13,520,120,042 and the total number of Shares entitling the Shareholders to attend and vote for or against Resolution no. 8 was 13,514,162,128;
 - (d) the total number of Shares entitling the Shareholders to attend and vote only against the Resolutions at the AGM was nil; and
 - (e) save as disclosed, there were no Shares entitling the holder to attend and abstain from voting in favour of the Resolutions at the AGM as set out in Rule 13.40 of the Listing Rules, no Shareholders were required under the Listing Rules to abstain from voting on the Resolutions, and there were no Shareholders that had stated their intention in the Circular to vote against or abstain from voting in respect of any Resolutions proposed at the AGM.
- (3) The Directors that attended the AGM were Mr. ZHU Shunyan, Mr. TU Yanwu, Mr. LI Faguang, Mr. WONG King On, Samuel and Ms. HUANG Yi Fei (Vanessa).
- (4) Tricor Secretaries Limited, the Company's branch share registrar and transfer office in Hong Kong, was appointed as the scrutineer at the AGM for the purpose of vote-taking in respect of the Resolutions.

As more than 50% of the total votes were cast in favour of each of Resolutions no. 1 to no. 8, these Resolutions were duly passed as ordinary resolutions of the Company.

As more than 75% of the total votes were cast in favour of Resolution no. 9, Resolution no. 9 was duly passed as a special resolution of the Company.

By order of the Board
Alibaba Health Information Technology Limited
ZHU Shunyan
Chairman and Chief Executive Officer

Hong Kong, August 5, 2022

As at the date of this announcement, the Board comprises seven Directors, of whom (i) three are executive Directors, namely Mr. ZHU Shunyan, Mr. SHEN Difan and Mr. TU Yanwu; (ii) one is a non-executive Director, namely Mr. LI Faguang; and (iii) three are independent non-executive Directors, namely Mr. LUO Tong, Mr. WONG King On, Samuel and Ms. HUANG Yi Fei (Vanessa).